All posts by imreal

HARTMANN USA and Corstrata Collaborate to Improve Patient Wound Outcomes


HARTMANN USA and Corstrata announce their collaboration to support home health and other in-home providers in caring for wound patients at a time when the incidence of complex chronic wounds is increasing while access to wound care nurse specialists is becoming more challenging. At the core of a successful wound care program is access to both highly effective advanced wound dressings as well as clinical expertise to implement evidence-based treatment protocols and monitor wounds to closure. According to a recent study published by top-50 accounting firm BerryDunn, National Healthcare at Home Best Practices and Future Insights Study, 100% of Home Health Centers of Excellence (those Home Health agencies in the top 10% for quality and patient satisfaction and with a positive financial surplus) have a wound-certified specialist on staff.

This collaboration will increase access to Corstrata’s team of virtual board-certified wound nurses (WOC nurses) and HARTMANN’s suite of advanced wound care products to improve clinical and financial outcomes for in-home providers that care for patients with chronic wounds.

HARTMANN has been providing advanced wound dressing solutions globally for over 150 years and has evolved with its broad portfolio of high-quality, cost-effective products that provide home health clinicians with a simplified, consistent approach for effectively managing wounds. Corstrata provides virtual wound and ostomy care management nationwide across multiple provider settings, including home health, skilled nursing facilities, hospice, and emerging hospital-at-home solutions companies.

According to Jon Procopio, Managing Director of HARTMANN USA, “Patient care is our priority. HARTMANN strives to enable the progression of the wound towards complete healing that patients deserve and strengthen the confidence that healthcare professionals need to provide wound care. We have a nationwide team of dedicated account and customer care representatives specifically trained for consultation, education, and support in offering clinical and business solutions. Now, with Corstrata, we will enhance access to clinical expertise related to wound care through their team of certified WOC nurses.”

“The Corstrata team is excited about this important collaboration with HARTMANN to create access to Corstrata’s virtual WOC nurses for customers and the patients they serve. With up to one-third of all home health and hospice patients having a chronic wound, it is critical for clinicians to provide evidence-based care to both prevent and heal wounds,” says Joseph Ebberwein, co-founder and Chief Financial Officer of Corstrata. “At this time when agencies are struggling with critical staffing shortages, including WOC nurses, and increasing financial challenges, having a strong wound program is essential. This collaboration between Corstrata and HARTMANN provides a path to success.”

According to Katherine Piette, Corstrata’s CEO, the decision to collaborate with HARTMANN is an easy one. “Our virtual WOC nurses rely on our provider customers having access to highly effective advanced wound dressings to accelerate wound healing and reduce the overall cost of patient care, ” Piette says. “HARTMANN has a unique suite of advanced dressings that are being used by some of the top home health providers in the U.S. with impressive results. We are excited about the opportunity to improve the level of wound care provided for this ever-growing cohort of complex wound patients. Our clients can access clinical support from Corstrata when needed without the cost of hiring their own WOC nurse, a costly and often frustrating proposition. This collaboration will equip providers with turn-key wound solutions that they have been missing in their clinical care delivery at a crucial time in the industry.”

About HARTMANN

The HARTMANN GROUP is one of the leading providers of wound treatment and skin integrity solutions around the world. Wound dressings and maintaining healthy skin have been at the heart of HARTMANN from the beginning when we introduced the world’s first antiseptic wound dressing over 150 years ago. Overall, HARTMANN looks at rich legacy. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®) and Infection Management (e. g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” In 2021, the HARTMANN GROUP reported Group sales of EUR 2.3 billion.

For the latest information on HARTMANN, follow @HARTMANN_GROUP on Twitter.

To learn more about the HARTMANN GROUP, click here.

To learn more about HARTMANN USA, click here.

About Corstrata

Corstrata is a virtual care solution that utilizes technology to provide access to scarce certified wound and ostomy nurses at the patient’s bedside in post-acute provider settings, including home health, hospice, skilled nursing facilities, and emerging hospital-at-home providers. Corstrata’s team of WOC nurses provides consultations with provider staff at the patient’s bedside, either through HIPAA-compliant video or through review of store-and-forward wound images, to improve clinical and financial outcomes for providers.

For the latest information on Corstrata, follow @Corstrata on Twitter.

To learn more about Corstrata, click here.

Share article on social media or email:



Dr. Gary Motykie Wins Best Botched Patient Enhancement at the 2022 Aesthetic Awards


Approximately half of the cases I perform are revising other surgeons’ work. To be recognized for my ability to perform revision plastic surgery is an honor.

Beverly Hills board-certified plastic surgeon, Dr. Gary Motykie, has won Best Botched Patient Enhancement at the 2022 Aesthetic Awards.

“Being selected as a winner in the Botched Revision category is especially exciting for me because you have to earn a previously ‘botched’ patient’s trust and confidence in order to perform their revision surgery,” says Dr. Motykie. “Approximately half of the cases I perform are revising other surgeons’ work. To be recognized for my ability to perform revision plastic surgery is an honor.”

“No patient wants to have to go through with revision plastic surgery. I know the process can be intimidating,” added Dr. Motykie. “I’m so grateful that I can be the surgeon that can help patients achieve the results they truly desired from their initial surgery.”

Dr. Motykie’s state-of-the-art office, on-site surgical center, and medical spa are at 9201 W. Sunset Blvd, GF-1A in West Hollywood. Dr. Motykie is known for pioneering facial rejuvenation surgery and natural-appearing body enhancement surgery.

“This year my team and I have narrowed in on promoting extraordinary outcomes by incorporating stem cells into the recovery process for patients. I believe stem cells make recovering from revision surgery easier on the patient.”

Dr. Motykie recently joined TikTok – he regularly uploads videos about plastic surgery trends, speculates on celebrity plastic surgery, and discusses plastic surgery procedures. He has amassed more than 4 million views in less than one month.

In addition to his West Hollywood flagship location, Dr. Motykie owns a medical spa, Motykie Med Spa Barrington, in the northwest Chicago suburb of Barrington, Illinois.

About Dr. Gary Motykie:

Dr. Gary Motykie is a Board-Certified Plastic Surgeon who is highly skilled in breast surgery, body contouring, rhinoplasty, and facial rejuvenation as well as numerous other cosmetic surgical procedures. Dr. Motykie has more than 50,000 subscribers on YouTube where he uploads videos discussing celebrity plastic surgery, plastic surgery secrets and procedures, and other cosmetic innovations. Patients and fans can view his surgical transformations on his Instagram, @DrGaryMotykie, which boasts more than 165,000 followers

Share article on social media or email:



Healthcare providers on the front line screening for diabetes, cancer and heart disease; What about addiction?


Join us for this comprehensive two-day conference integrating the latest research in mental health with traditional medical practices. Discussions will focus on how to improve access, engagement, and patient outcomes, giving healthcare practitioners the tools they need to assess behavioral traits before a critical disease state. Conference participation provides continuing medical education (CME) credits and contact hours for students and healthcare practitioners towards state-mandated requirements. This innovative curriculum was developed in partnership with ThriveX™, Axis Medical Education, and Northeast College of Health Science and features a panel of experts addressing the addiction crisis.

To learn more visit and register today: https://thrivex.com/edu

Panel Experts Include:

Michael Sension MD, AAHIVM, CAN Community Health, is an internist and specialist in HIV medicine and is the medical director of Can Community Health in Plantation, Florida. Previously, Dr. Sension was the medical director of HIV Clinical Research for Broward Health in Ft. Lauderdale, Florida. Dr. Sension earned his undergraduate degree from Wheaton College in Wheaton, Illinois, and his medical degree from Johns Hopkins School of Medicine in Baltimore, Maryland. He completed his internship and residency at Cornell University, New York Hospital in New York, New York, and did additional training in infectious diseases at the National Institute of Health in Bethesda, Maryland. He has been the principal investigator of numerous clinical trials and lectures frequently on the topic of HIV treatment and prevention.

Mitchell J. Ghen, DO, Ph.D. has 38 years of experience in anti-aging and holistic and integrative medicine. Along with his work in nutritional medicine, Dr. Mitch has a remarkable amount of experience as an expert clinician and researcher in the field of umbilical cord tissue research. Dr. Mitch holds a Master’s Degree in Biomechanical Trauma and has a Ph.D. in Nutrition and Psychoneuroimmunology.

Antonio De Felippo, MD, Psychiatry, Psychosomatic Medicine, and Addiction Medicine received his medical degree from the University of South Florida Morsani College of Medicine and has been in practice for more than 20 years. He has worked extensively in Addiction, Recovery, and Psychosomatic Medicine. He is presently a pioneer in the treatment of multi-drug-resistant depression and transcranial magnetic stimulation.

Conference Highlights Include:

  • Physical and Psychiatric Co-morbidities that Predispose Patients to SAB
  • Findings in Patients in Recovery
  • Interventional Non-Opiate Pain Management
  • Understanding Different Treatment Programs Available and Proper Documentation and Coding for Clinical Services Rendered.

Share article on social media or email:

SGF research team presents 19 studies at this year’s ASRM Scientific Congress, demonstrating its commitment to continuously improving outcomes for fertility patients


SGF presents 19 studies at this year’s American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo, including a prize paper and 8 oral presentations.

“Year after year, the SGF research team is proud to participate in the ASRM Scientific Congress and Expo and collaborate with reproductive scientists from the U.S. and around the world to improve outcomes for those facing infertility.”

Shady Grove Fertility’s (SGF) physician-scientists will present 19 research abstracts during the 2022 American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo as part of the practice’s commitment to advancing knowledge and improving assisted reproductive technology (ART) treatment outcomes. This year’s research by SGF presented at ASRM covered many important topics care including optimized outcomes for frozen embryo transfers, third-party reproduction, male fertility, and fertility preservation for patients with cancer, to name a few.

Hosted in Anaheim, California, the 78th ASRM Scientific Congress & Expo takes place October 22 through 26, 2022, and attracts more than 8,000 national and international physicians and professionals — distinguished academicians, clinicians, and scientific investigators in the field of human reproduction. The theme of the ASRM 2022 meeting is Genes, Gametes, and Genetics: What Will the Future Hold?

SGF is one of only a few private practice fertility centers in the country to employ a full-time dedicated research team, which operates under Director of Research, Kate Devine, M.D., a board certified reproductive endocrinologist who sees patients at SGF’s Washington, D.C., K Street location. Dr. Devine serves as faculty to fellows at the National Institutes of Health (NIH) training to become reproductive endocrinologists and to residents at Georgetown School of Medicine training to be obstetrician/gynecologists. Dr. Devine also serves as the Executive Medical Director and Chief Research Officer at US Fertility, the largest network of physician-owned and physician-led fertility practices in the United States, of which SGF is a founding partner practice.

“Year after year, the SGF research team is proud to participate in the ASRM Scientific Congress and Expo and collaborate with reproductive scientists from the U.S. and around the world to improve outcomes for those facing infertility,” shares Dr. Devine. “Our research efforts offer hope to those struggling to conceive and push us to continue providing innovative, evidence-based care to fertility patients.”

As a premier IVF and fertility center of excellence, SGF demonstrates a sustained commitment to clinical research and clinical education. Many of the studies presented at the meeting this year resulted from collaborations between SGF and academic institutions. SGF physicians act as clinical instructors and research mentors to physicians in training from NIH, Georgetown University, Eastern Virginia Medical School, University of South Florida, and University of Colorado.

“SGF is proud to be training the next generation of physicians in reproductive medicine,” shares Eric Widra, M.D., Chief Medical Officer, SGF. “Our valuable and unprecedented partnership with our four fellowship programs fuels our research initiatives and gives back to all fertility patients.”    

SGF’s national retrospective cohort study of ovarian response and anti-Mullerian hormone (AMH) in cancer patients undergoing fertility preservation treatment compared to patients who are electively freezing their eggs has been selected as the Fertility Preservation Special Interest Group Prize Paper Prize Paper. The research, led by University of Colorado fellow Ivy Lersten, M.D., alongside her mentor, SGF Colorado physician Cassandra Roeca, M.D., found that the relationship between the number of eggs retrieved or cryopreserved and AMH did not differ for fertility preservation versus elective egg freezing groups. This research can provide reassurance for patients undergoing fertility preservation treatment following a cancer diagnosis.

“At SGF, we know the importance of innovative, evidence-based fertility care,” shares Dr. Roeca. “With this new information, we can better counsel patients and reassure them that their cancer diagnosis does not have to mean the end of their family-building dreams.”

In addition to oral and poster presentations, several SGF physicians and nurses hosted symposiums, interactive sessions, roundtable discussions, and post-graduate courses. Jerrine Morris, M.D., an SGF physician who joined the practice this fall, will lead a roundtable discussion, symposia, and session that all dive into bringing diversity and equity to reproductive healthcare.

To learn more about ongoing research being conducted at SGF, visit http://www.shadygrovefertility.com/research.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 100,000 babies born from 30+ years of continuous innovation and patient-centered fertility care. With 50 locations, including the newest location in Raleigh, North Carolina, as well as throughout CO, FL, GA, MD, NY, PA, TX, VA, D.C., and Santiago, Chile, SGF offers patients in-person and virtual physician consults, delivers individualized care, accepts most insurance plans, and makes treatment affordable through innovative financial options, including 100% refund guarantees. SGF is among the founding partner practices of US Fertility, the largest physician-led partnership of top-tier fertility practices in the U.S. Call 1-888-761-1967 to schedule a new patient appointment or visit ShadyGroveFertility.com for more information.

Share article on social media or email:

Eyedaptic, Inc. unveils the EYE5 glasses with EyeSwitch™


“People value their eyesight over ten times more than any of their other senses. The EYE5 gives my patients with visual impairments access to life-changing technology to enhance their vision,” – Dr. Mitul Mehta, MD Vitreo Retinal Surgeon and Eyedaptic CMO.

Eyedaptic, Inc., is excited to unveil the all-new EYE5 smart glasses at the American Academy of Optometry 2022 Annual Meeting and Expo. Together with Augmented Reality Glasses manufacturer Rokid, Eyedaptic has partnered to deliver a technology solution to an issue biology can’t solve. The latest model brings wearability to a whole new level and covers the widest range of use cases for central vision loss including Diabetic Retinopathy and Age-Related Macular Degeneration (AMD).

Eyedaptic is a Southern California-based developer of game-changing augmented reality eyewear, designed in conjunction with ophthalmology retina specialists and optometrists, to aid those with retinal-related vision challenges. “People value their eyesight over ten times more than any of their other senses. The EYE5 gives my patients with visual impairments access to life-changing technology to enhance their vision. The ability to acquire the smart glasses through their eye care provider makes it more attainable as well” explains Dr. Mitul Mehta, MD Vitreo Retinal Surgeon and Eyedaptic’s Chief Medical Officer.

Equipped with patented simulated natural vision software, the Eyedaptic EYE5 solution optimizes the user’s functional peripheral vision through a small embedded camera that captures an individual’s environment, manipulates and enhances the pixels and re-displays the image, all enabled with hands-free controls. The newest product includes novel artificial intelligence and computer vision algorithms, such as facial detection, to allow the user to see what they have been missing. The newest features integrate seamlessly, while adding powerful technology, to Eyedaptic’s popular custom User Interface. Furthermore, the EYE5 still offers the EyeSwitch 2-in-1 functionality combining a wearable and a hand-held visual aid all in one product, thereby eliminating the need for multiple products for different tasks.

With the availability of Eyedaptic wearables, patients with retinal diseases can now be referred to solutions that enhance their quality of life, easily and unobtrusively. Recently, Eyedaptic was awarded its 6th patent grant. This latest patent extends the technology for Hybrid-See Through, helping to enable Augmented Reality for vision impairments and low vision applications.

Jay Cormier, Eyedaptic CEO says “we are proud to partner with California Bay Area-based Rokid who specializes in the research and product development of Mixed Reality and Artificial Intelligence. With the mission of “leave nobody behind”, Rokid provides the extreme user experience, superior products, and robust enterprise solutions for developing communities. Featuring best-in-class, high-resolution 1080p displays with a wide field of view coupled with a high-resolution autofocus camera, augmented reality has never been more accessible to make a positive and powerful impact on a broad range of industries.”

“Clinical studies have been conducted to demonstrate the utility and efficacy of Eyedaptic smart glasses. The clinical data demonstrated over a doubling in visual acuity and a five times improvement in daily activities. Because Eyedaptic eyewear is designed to be hands-free and not impede mobility, they are ideal for those managing a wide variety of tasks whether it be seeing a movie, grocery shopping, reading a restaurant menu or working at a computer. We are happy to be part of the mission of enhancing vision to revitalize life” says Liang Guan, Rokid North American Vice President and General Manager.

About Rokid

Rokid creates technology that revolutionizes work environments. With innovative products and professional AR solutions for vertical markets, Rokid partners can stand out in the marketplace and foster business growth to serve clients worldwide. For more information, please visit http://www.rokid.ai.

About Eyedaptic

Eyedaptic is a privately held company that develops technology-forward, market-leading wearable visual aid software, enabled by augmented reality hardware, for retinal diseases. The proprietary Simulated Natural Vision software goes beyond magnification to enhance and optimize the field of vision, for those suffering from central vision disorders such as Macular Degeneration, to revitalize their quality of life. For more information, please contact info@eyedaptic.com or visit @eyedaptic on Facebook, Twitter or LinkedIn. #SeeWhatYouveBeenMissing

Share article on social media or email:

How the University of Zagreb School of Medicine (UZSM) moved from conventional microscope histology teaching to online digital teaching with Pathomation


The University of Zagreb School of Medicine (UZSM) adopted Pathomation’s digital pathology for its transformation of microscopy education in 2021, under the impetus of the global COVID-19 pandemic. UZSM opted to incorporate both PMA.core and PMA.slidebox into its microscopy education curriculum, as it made it convenient for students to have both access to (virtual) slide-material during off-hours, as well as for lecturers to offer hands-on teaching materials to students while quarantine and social distancing measures were enforced. UZSM made this transition in the context of limited resources and high time pressure, fully conscious of the perceived disadvantages of digital pathology like implementation complexity, insufficient IT infrastructure and slow image loading experience for users.

“We had been using Pathomation for the European School of Pathology (EScoP) lecture series since 2015, this gave us the confidence that the Pathomation solution could also be used for student distance learning in UZSM.”, recalls Sven Seiwerth, department head and professor of pathology. “It took a global pandemic to move ahead with a broader application into regular teaching”, he laughs, “but we’re very satisfied we’ve made the move; instructors can prepare their lectures in a central secure location, and students tell me the software is really easy to use; all they need is a web browser”.

When asked what his tips for other institutes were that want to start with digital pathology, professor Seiwerh answered “I was most worried about the reaction of my IT department, they were already overloaded due to the pandemic remote work requirements and I thought that integrating digital pathology would be very complex. But the Pathomation software is designed to be integrated in learning environments and the Pathomation team provided great support answering all the questions of our IT department. It only took us two months from start to finish to complete the implementation, the longest part being the scanning of our student’s histopathology collection.”

“The experience of UZSM proves that adopting digital pathology for teaching is within the reach of all and that it can improve students access to teaching.” says Rudy Hovelinck, Pathomation’s Chief Operating Officer Office (COO). “This is a further demonstration that PMA.core and PMA.slidebox are robust and easy to implement products that support a swift transition to digital education. We also continue to expand our offer for academic teaching to meet growing global demands like the recent new release of our My Pathomation online platform.”

About Pathomation: Pathomation was founded in Belgium in 2012. Its free software, PMA.start, has global adaptation and is used at 450+ sites each month. Its online My Pathomation cloud platform hosts a community of 750 users and offers free 10 GB accounts. PMA.core is a clinical diagnostic use CE-IVD certified tile server targeted at any organization that interacts with digital pathology and virtual microscopy data. Pathomation software supports over 35 different proprietary file formats. Visit the company’s website at https://www.pathomation.com/

About UZSM: The School of Medicine in Zagreb is a Croatian medical school affiliated with the University of Zagreb. It is the oldest and biggest of the four medical schools in Croatia, having been established in 1917 and with around 1800 students enrolled in the Croatian MD program, 300 in Medical Studies in English, 60 in the Nurses Master program and more than 1000 in different postgraduate programs. Visit the school’s website at https://www.mef.hr

Share article on social media or email:

90% of pharma & biotech companies are already registered in EMA’s new clinical trials information system (CTIS), Arriello survey finds


It is encouraging to find such an enthusiastic early response, which we hope will continue to bear out as companies use it more actively to process applications for new trials.

Arriello, a leading global provider of Regulatory, Quality, Safety/PV and Clinical advisory and process support services, has found surprising evidence of strong, early engagement with EMA’s new definitive, centralized registration system for clinical trials, CTIS, despite its use not being mandatory for new clinical trials until after January 31, 2023.

Already, over 90% of pharma and biotech companies polled across the UK, Germany, Switzerland, and the US say they are registered in the CTIS; 40% have submitted a clinical trials application (CTA); and just over 17% have applications pending, according to the survey, conducted in August among 400 relevant Director and/or relevant Functional Heads in Pharma, Biotech and CRO companies.

The new platform and portal are designed to streamline the submission, assessment and approval of trials across EU markets, under the new Clinical Trials Regulation (CTR) which became applicable at the end of January 2022 and will be mandatory for all new clinical trials from January 31, 2023.

The online Censuswide survey, split evenly across the four geographical markets, found that early experiences of the process to be positive – a step in the right direction toward the long-promised aim of easier clinical trial harmonization in Europe.

With the deadline for compliance with CTR and CTIS use looming, it is to be expected that teams will increasingly default to the new platform and process, to remove the risk of having to transition to it part way through a trials program. Overall, 92% of respondents said their organization was planning a clinical trial through the centralized EMA system over the coming six months, with Switzerland then Germany recording the highest responses (98% and 96% respectively).

Speed & efficiency among the key benefits

Of the high proportion of organizations that had already registered a trial through the CTIS, more than a third (37 percent) reported they had found the experience faster/shorter than expected, and 31 percent said the process had been easier than expected. Three-quarters of companies had registered a trial through the CTIS found assessment deadlines had been achieved, rising to 99% of US organizations.

All respondents appeared to have a good grasp of and appreciation for the intended benefits of CTR and the CTIS, ranked as:

1. Faster approvals – an expected advantage for 35% of respondents (rising to 40% in the US)

2. Benefits of a wider group experience – cited by 33%

3. Efficiency of scale – cited by 30%

4. Harmonization of processes – 28%

5. Greater transparency – 28% (rising to 40% of US respondents while falling to 16% of Swiss respondents)

6. Fostering innovation & research – 26% (falling to 16% of Swiss respondents)

7. Supporting more uniform decisions – 25%.

Issues to iron out

Experiences of the new portal haven’t been pain-free, though there was no obvious single point of concern. Source of friction to date include:

  • Issues of organizational structure – cited by 38% of respondents overall, rising to 43% of US respondents
  • Training/information overload – cited by 36%
  • Transition point identification – an issue for 35%
  • Fear of the unknown – cited by 33%
  • A lack of clearly defined process steps – cited by 33%.

Swiss respondents were least likely to have significant issues, and the UK participants’ responses were most evenly spread across the different barriers. German and US respondents expressed most concern about organizational and process issues.

Commenting on the findings, Kieran O’Donnell, Vice President, Global Drug Safety at Arriello, said, “The response of the industry to the new consolidated EMA clinical trials platform to date is overwhelmingly positive, much more so than anecdotal evidence had suggested. This shows just how much this resource is needed in the European market which many companies have found hard to navigate up to now, due to its diverse requirements.

“It is encouraging to find such an enthusiastic early response, which we hope will continue to bear out as companies use it more actively to process applications for new trials.”

The full survey findings are free to download from the Arriello web site, here. They will also be discussed at a fireside chat at Bio Europe on Monday 24th at 09:30 am.

About Arriello

Arriello has been providing risk management and compliance services to the life sciences sector since 2008. These services include market consultancy, global regulatory affairs strategy and implementation, full and local pharmacovigilance solutions, clinical drug safety and quality and compliance auditing systems.

Headquartered in Ireland, with European operations in Central Europe, our technical team has a combined experience of over 130 years working across the EU, US, LATAM, MENA, CIS, APAC regions and South Africa.

More at http://www.arriello.com and @Arriello

Media contact:

Carina Birt

Sarum Life Sciences for Arriello

carina@sarumlifesciences.com

+44 7970 006624

Share article on social media or email:

Liberty Sports Park Opens, the Mid-Atlantic Region’s Premier Youth and Adult Field Sports Vacation Destination


Liberty-Sports_Park_Logo

“This is a long-awaited and momentous day,” said Douglas J.J. Peters, former Maryland District 23 state senator. “Liberty Sports Park is a big win for youth and adult sports, area businesses and the entire state of Maryland.”

Liberty Sports Park, the Mid-Atlantic Region’s premier field sports vacation destination, marked its grand opening today as youth and adult soccer, lacrosse and field hockey leagues based in Washington, D.C., Virginia and Maryland, as well as Prince George’s County recreational football teams held scrimmages and practices at the complex.

Located at 220 Prince George’s Boulevard in Upper Marlboro, Md., Liberty Sports Park features 10 lit fields – six turf and four grass – available for youth and adult league, club and other soccer, lacrosse, field hockey, football and rugby programs, as well as Prince George’s County Public Schools, Prince George’s Community College and the Prince George’s County Boys and Girls Club.

“This is a long-awaited and momentous day,” said Douglas J.J. Peters, former Maryland District 23 state senator. “Liberty Sports Park is a big win for youth and adult sports, area businesses and the entire state of Maryland.”

The facility features onsite hotel rooms, restaurants, entertainment and more at South Lake, an adjacent mixed-use community currently under construction.

“Liberty is unlike any other complex in greater Washington and serves as a new anchor for the 301-214 corridor,” said Thomas H. Graham, chair of the executive board for Green Branch Foundation, a nonprofit organization that manages the park’s day-to-day operations. “The tournaments and events that will take place at Liberty, matched with the attractions the South Lake development will offer, brings new life to the area.”

Liberty, through its location, projected attendees and nearby amenities, is expected to bring substantial economic benefits to both Prince George’s County and the state of Maryland. The park is expected to generate up to 360 new jobs and between $28.1 million and $31.3 million of spending in Prince George’s County, as well as up to 180 jobs and $14.4 million to $16 million in the state.

Fields are expected to be in use 30 weekends each year, with roughly 344,800 total visits. Already in high demand, fields are fully booked through the Thanksgiving holiday weekend.

Liberty Sports Park is the result of a unique, years-long public-private partnership. Community partners include the state of Maryland, Prince George’s County government, Washington Commanders Charitable Foundation, NAI Michael Cos, South Lake, St. John Properties, Truist Foundation, Buch Construction, Green Branch Foundation and Oak Hill Strategies.

The complex is conveniently located south of Central Avenue on the southbound side of US 301 in Prince George’s County, minutes away from Washington, D.C., Baltimore, Annapolis and other popular area attractions.

Photos from the grand opening will be uploaded to the Liberty website for media and public use.

###

About Liberty Sports Park: Liberty Sports Park is the Mid-Atlantic Region’s premier field sports vacation destination. With onsite dining, hotel and entertainment options just footsteps away from its 10 turf and grass fields, visitors can eat, play and stay in one place. Conveniently located in Prince George’s County, Maryland, minutes away from Washington, D.C., Baltimore and other popular area attractions, Liberty Sports Park will be in use 30 weekends each year with more than 344,800 visits annually. To learn more, visit http://www.libertysportspark.com.

About Green Branch Foundation: Green Branch Foundation is a community-based nonprofit charitable 501(c)(3) organization based in Prince George’s County. Committed to the education and development of sports programs and competitions for youth, adults, families and communities, the Foundation’s mission is to provide youth with greater access and exposure to athletics. Green Branch Foundation believes organized athletics provide a greater opportunity for youth to live healthier lifestyles, allow for personal growth in a positive environment, promote mentorship with community leaders and lead to greater scholarship opportunities for college.

Share article on social media or email:

Cristaux International Celebrates Its 15th Anniversary This Month


Cristaux-custom-awards

Custom Awards by Cristaux

The Cristaux team spent ten years refining its craft in a niche space, carving out a place for modern and substantial recognition. In the last five years, Cristaux has transformed into a solutions mastermind.

This month, Cristaux International, a global leader in custom awards manufacturing and innovator of recognition program fulfillment, celebrated its fifteenth business anniversary. After starting the business from the founder’s parents’ basement, Cristaux has since pushed the envelope with revolutionary ideas and continues to grow its capabilities.

Of the company’s recent turning point, Cristaux Founder and Chief Creative Officer, Andre Janus said, “We were one of the pioneers to offer custom awards and recognition. I’m very proud to see that after 15 years, Cristaux works with brand-oriented and cutting-edge organizations, helping manifest stories of accomplishment. It’s about to get a lot more fun as we expand operations to service client needs throughout Europe and the Middle East.”

The Cristaux team spent ten years refining its craft in a niche space, carving out a place for modern and substantial recognition. In the last five years, Cristaux has transformed into a solutions mastermind. Whether working with the Smithsonian Institution or Anheuser-Busch, Cristaux melds creative manufacturing with global fulfillment to realize thousand-piece programs around the world.

The company plans to be operationally ready in Europe by mid-2023. Stateside, Cristaux continues to expand its roots and bandwidth in the largest industrial park of North America. With plans to double its square footage in Chicago, Cristaux is also expanding its inventory allocation, dedicated departments, ultramodern machinery, and more to support its ever-growing clientele.

About Cristaux International: Cristaux International is an elite manufacturing company that specializes in creative design for custom awards and recognition solutions like drop shipping and inventory management. Founded in 2007, Cristaux has evolved its offerings to support its clients including the James Beard Foundation and World Poker Tour. Cristaux was voted one of the 101 top Illinois product design companies of 2021 by BestStartup.us. Also, Cristaux was named one of the 2018 Best Places to Work in Illinois.

Share article on social media or email:



Amplifi Hearing Announces Release of EarScript™ Hearing Aid Comparison App


Amplifi Hearing, a new company focused on advancing hearing care delivery today announced the release of EarScript, an iPad app that makes comparing and selecting a hearing aid based on a patient’s own hearing profile a reality.

Amplifi was formed in 2021 by industry veterans, with a mission to help move the needle on how hearing care is delivered. EarScript is a patented* process that enables a patient to listen to a variety of hearing aids in different listening conditions that is tailored to their own hearing pattern and offers a new and better way to compare and select the best hearing device for their needs.

EarScript was developed and patented by Dr. Andre Marcoux in 2015 as a way to provide his patients with a better and more engaged level of hearing care. Amplifi Hearing has acquired the product and patent to bring EarScript to the global market, with initial focus on the United States and Canada.

The EarScript process is covered by both U.S. and Canadian patents and is both easy to install and use and acts as a great sales and marketing tool for hearing care providers. The app can save time for both hearing care professionals and patients, and result in fewer returns.

The recording process for the hearing aids available through EarScript is rigorous and carefully controlled so that a true comparison of different devices can be offered in listening conditions including speech in noise, speech in quiet, and both jazz and orchestral samples for each hearing aid. Various hearing patterns are recorded for each hearing aid, which enables the patient to hear the various aids in a way that closely matches their hearing condition.

The EarScript iPad app is offered as a downloadable software on either annual or semi-annual subscription basis and is very affordable for hearing care professionals and device manufacturers.

For more information about this exciting new product, please contact Amplifi Hearing at +1 610.590.1590 or visit the product webpage at http://www.earscript.com.


  • U.S. Patent 9,154,888 Canadian Patent 2,876,251

Share article on social media or email: